Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News AnaptysBio Inc ANAB

Healthcare Biotechnology
AnaptysBio, Inc. is a clinical-stage biotechnology company focused on delivering immunology therapeutics. The Company is developing immune cell modulators, including two checkpoint agonists for autoimmune and inflammatory disease: rosnilimab, its PD-1 agonist, in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis; and ANB032... see more

Recent & Breaking News (NDAQ:ANAB)

AnaptysBio Reports Etokimab ATLAS Phase 2b Clinical Trial in Moderate-to-Severe Atopic Dermatitis Fails to Meet Primary Endpoint

GlobeNewswire November 8, 2019

AnaptysBio Reports Positive Topline Data from Interim Analysis of GALLOP Phase 2 Clinical Trial of ANB019 Monotherapy in Moderate-to-Severe Generalized Pustular Psoriasis

GlobeNewswire September 30, 2019

AnaptysBio to Present at the Cantor Fitzgerald Global Healthcare Conference

GlobeNewswire September 27, 2019

AnaptysBio Announces Second Quarter 2019 Financial Results and Provides Pipeline Updates

GlobeNewswire August 8, 2019

AnaptysBio to Present at the Wedbush PacGrow 2019 Healthcare Conference

GlobeNewswire August 6, 2019

AnaptysBio Presents Updated Data from Etokimab Phase 2a Proof-of-Concept Clinical Trial in Severe Eosinophilic Asthma

GlobeNewswire June 5, 2019

AnaptysBio to Present at the Jefferies 2019 Healthcare Conference

GlobeNewswire May 28, 2019

AnaptysBio Announces First Quarter 2019 Financial Results and Provides Pipeline Updates

GlobeNewswire May 7, 2019

AnaptysBio to Present at the Bank of America Merrill Lynch Healthcare Conference

GlobeNewswire May 1, 2019

AnaptysBio to Present at the Cowen and Company 39th Annual Health Care Conference

GlobeNewswire March 4, 2019

AnaptysBio Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Pipeline Updates

GlobeNewswire February 28, 2019

AnaptysBio to Present at J.P. Morgan 37th Annual Healthcare Conference

GlobeNewswire January 2, 2019

The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial

Benzinga.com  December 21, 2018

The Daily Biotech Pulse: Pfizer-Glaxo Set Up Consumer Health Care Venture, New Patent For Adamas

Benzinga.com  December 19, 2018

Research Report Identifies Ebix, Gold Resource, Mastech Digital, AmeriGas Partners, Tactile Systems Technology, and AnaptysBio with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

GlobeNewswire November 26, 2018

The Daily Biotech Pulse: FDA Nod For Mallinckrodt's Pain Drug, AbbVie-Neurocrine Report Positive Elagolix Results

Benzinga.com  November 15, 2018

AnaptysBio Announces Third Quarter 2018 Financial Results and Provides Pipeline Updates

GlobeNewswire November 8, 2018

AnaptysBio to Participate in Upcoming Investor Conferences

GlobeNewswire November 5, 2018

AnaptysBio Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option

GlobeNewswire September 28, 2018

AnaptysBio Announces Pricing of Public Offering of Common Stock

GlobeNewswire September 25, 2018